A tunable dual-promoter integrator for targeting of cancer cells

Precise discrimination between similar cellular states is essential for autonomous decision‐making scenarios, such as in vivo targeting of diseased cells. Discrimination could be achieved by delivering an effector gene expressed under a highly active context‐specific promoter. Yet, a single‐promoter approach has linear response and offers limited control of specificity and efficacy. Here, we constructed a dual‐promoter integrator, which expresses an effector gene only when the combined activity of two internal input promoters is high. A tunable response provides flexibility in choosing promoter inputs and effector gene output. Experiments using one premalignant and four cancer cell lines, over a wide range of promoter activities, revealed a digital‐like response of input amplification following a sharp activation threshold. The response function is cell dependent with its overall magnitude increasing with degree of malignancy. The tunable digital‐like response provides robustness, acts to remove input noise minimizing false‐positive identification of cell states, and improves targeting precision and efficacy.

[1]  J. Thevelein,et al.  Budding yeast as a screening tool for discovery of nucleoside analogs for use in HSV-1 TK suicide-gene therapy. , 1999, BioTechniques.

[2]  S. Semple-Rowland,et al.  Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters. , 2007, Molecular vision.

[3]  Farren J. Isaacs,et al.  Tracking, tuning, and terminating microbial physiology using synthetic riboregulators , 2010, Proceedings of the National Academy of Sciences.

[4]  M. Fussenegger,et al.  Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. , 2002, Nucleic acids research.

[5]  L. Nissim,et al.  An autonomous system for identifying and governing a cell's state in yeast , 2007, Physical biology.

[6]  J. Hopfield Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Andreadis,et al.  Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector , 2009, Gene Therapy.

[8]  A. Hoffmann,et al.  Transcriptional regulation via the NF-kappaB signaling module. , 2006, Oncogene.

[9]  Eytan Domany,et al.  The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation , 2005, Molecular systems biology.

[10]  R. Strieter,et al.  CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer , 2006, The Journal of experimental medicine.

[11]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[12]  W. Ramsey,et al.  The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication , 1998, Gene Therapy.

[13]  J. Yee,et al.  Gene expression from transcriptionally disabled retroviral vectors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Chen,et al.  Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells , 2005, Gene Therapy.

[15]  R. Müller,et al.  A synthetic leucine zipper-based dimerization system for combining multiple promoter specificities , 2001, Gene Therapy.

[16]  E. Small,et al.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  X. Zhan,et al.  Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Ying Huang,et al.  Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer , 2004, Cancer Gene Therapy.

[19]  V. Rotter,et al.  Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. , 2003, Cancer research.

[20]  D. Yee,et al.  Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells , 2000, Breast Cancer Research and Treatment.

[21]  F. Guerlesquin,et al.  Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein , 2007, Proceedings of the National Academy of Sciences.

[22]  Christopher A. Voigt,et al.  Environmental signal integration by a modular AND gate , 2007, Molecular systems biology.

[23]  V. Rotter,et al.  Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.

[24]  Y. Tesfaigzi,et al.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.

[25]  O. Gofrit,et al.  Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer , 2004 .

[26]  James J. Collins,et al.  A Tunable Genetic Switch Based on RNAi and Repressor Proteins for Regulating Gene Expression in Mammalian Cells , 2007, Cell.

[27]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.

[28]  S. Kain,et al.  Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter* , 1998, The Journal of Biological Chemistry.

[29]  Wendell A. Lim,et al.  Designing customized cell signalling circuits , 2010, Nature Reviews Molecular Cell Biology.

[30]  Özlem Türeci,et al.  SSX: A multigene family with several members transcribed in normal testis and human cancer , 1997, International journal of cancer.

[31]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[32]  Zhen Xie,et al.  Rationally-designed logic integration of regulatory signals in mammalian cells , 2010, Nature nanotechnology.

[33]  J. Nör,et al.  Transcriptional targeting of tumor endothelial cells for gene therapy. , 2009, Advanced drug delivery reviews.

[34]  P. Kantoff,et al.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Kevin C. Chen,et al.  A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[36]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[37]  I. Stratford,et al.  Targeting gene therapy to cancer: a review. , 1997, Oncology research.

[38]  M. Ptashne How eukaryotic transcriptional activators work , 1988, Nature.

[39]  A. Abbruzzese,et al.  Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. , 2000, European journal of biochemistry.

[40]  R. Müller,et al.  Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. , 1998, Human gene therapy.

[41]  A. Hoffmann,et al.  Transcriptional regulation via the NF-κB signaling module , 2006, Oncogene.

[42]  E. Bayer,et al.  Functional asymmetry in cohesin binding belies inherent symmetry of the dockerin module: insight into cellulosome assembly revealed by systematic mutagenesis. , 2008, The Biochemical journal.

[43]  R. Naviaux,et al.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses , 1996, Journal of virology.

[44]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[45]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[46]  E. Bayer,et al.  Matching fusion protein systems for affinity analysis of two interacting families of proteins: the cohesin–dockerin interaction , 2005, Journal of molecular recognition : JMR.

[47]  E. Mekada,et al.  One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell , 1978, Cell.

[48]  D. Nettelbeck,et al.  Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. , 2009, Advanced drug delivery reviews.

[49]  D. Nettelbeck Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer , 2008, Journal of Molecular Medicine.

[50]  Martin Fussenegger,et al.  Recent advances in mammalian synthetic biology-design of synthetic transgene control networks. , 2009, Current opinion in biotechnology.

[51]  V. Rotter,et al.  p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.

[52]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[53]  P. Nilsson,et al.  Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis , 2007, Cell Death and Differentiation.

[54]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[55]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[56]  S. Thorne,et al.  Dual Promoter–Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models , 2005, Clinical Cancer Research.